Inpefa: Uses, Dosage, Side Effects, Warnings - Drugs.com
2024年7月25日 · Inpefa (sotagliflozin) is a once-daily tablet that may be used to reduce the risk of cardiovascular death or hospitalization or urgent visits for heart failure in adults with heart failure, type 2 diabetes mellitus, chronic kidney disease, or other cardio
Heart Failure Treatment | INPEFA® (sotagliflozin) HCP
INPEFA® is an inhibitor of SGLT2 and SGLT1 for adults with heart failure or T2 Diabetes, CKD, and other CV risk factors. See Safety Info and full Prescribing Information. Learn more
Sotagliflozin - Wikipedia
In May 2023, the US FDA approved sotagliflozin (Inpefa) to decrease the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk.
Inpefa Oral: Uses, Side Effects, Interactions, Pictures ... - WebMD
Sotagliflozin is used by people with heart failure or by people with type 2 diabetes, kidney disease, and other heart disease risk factors to lower the risk of death from heart disease and to...
Inpefa (sotagliflozin): Uses, Side Effects, Dosage & Reviews - GoodRx
2023年6月25日 · Inpefa (sotagliflozin) is a newer medication that's approved to lessen the risk of heart-related complications in people with heart failure and in people with Type 2 diabetes, chronic kidney disease (CKD), and other heart-related conditions.
INPEFA- sotagliflozin tablet - DailyMed
2024年1月15日 · INPEFA® (sotagliflozin) tablets, for oral use - Initial ... INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or - type 2 diabetes mellitus ...
• Sotagliflozin is an SGLT2 inhibitor indicated to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), and urgent heart failure visit in adults with: o heart failure or
Inpefa (sotagliflozin)中文说明书-价格-适应症-不良反应及注意事项
2023年5月26日，美国食品药品监督管理局 (FDA)已批准Lexicon Pharmaceuticals制药公司的Inpefa (sotagliflozin)，用于可降低心血管死亡、心力衰竭住院和成年人紧急心力衰竭就诊的风险，具体为患有:心力衰竭或者二型糖尿病糖尿病、慢性肾脏疾病和其他心血管危险因素。 该药物是首个FDA批准的SGLT1和SGLT2双重抑制剂，属于一类可通过抑制SGLT1和SGLT2蛋白来帮助调节血糖水平并降低体重增加的风险的药物。 该批准是基于对心力衰竭或有心力衰竭风险的患 …
Inpefa (sotagliflozin) dosing, indications, interactions, adverse ...
Medscape - Heart failure dosing for Inpefa (sotagliflozin), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.
Clinical Overview: Sotagliflozin (Inpefa) for Heart Failure
2023年10月27日 · The FDA approved sotagliflozin (Inpefa) in May 2023 for the purpose of lowering the risk of cardiovascular death and heart failure in adult patients with heart failure, type 2 diabetes mellitus, chronic kidney disease, and additional cardiovascular risk factors. 1 Sotagliflozin is an orally administered dual SGLT1/2 inhibitor that achieves its ...
- 某些结果已被删除